Gesine Meyer-Rath to Anti-HIV Agents
This is a "connection" page, showing publications Gesine Meyer-Rath has written about Anti-HIV Agents.
Connection Strength
3,407
-
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
Score: 0,439
-
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
Score: 0,413
-
The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
Score: 0,369
-
Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
Score: 0,310
-
Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
Score: 0,310
-
Prospects for HIV control in South Africa: a model-based analysis. Glob Health Action. 2016; 9:30314.
Score: 0,282
-
HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med. 2012; 9(7):e1001247.
Score: 0,215
-
The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009 Nov; 21(11):1388-94.
Score: 0,178
-
The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS. 2024 03 15; 38(4):589-594.
Score: 0,118
-
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265.
Score: 0,111
-
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
Score: 0,106
-
Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
Score: 0,099
-
The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case. PLoS One. 2019; 14(2):e0210497.
Score: 0,085
-
Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study. PLoS One. 2017; 12(6):e0178249.
Score: 0,076
-
Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLoS Med. 2017 02; 14(2):e1002240.
Score: 0,074
-
Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
Score: 0,063
-
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis. 2014 Jan 09; 14:14.
Score: 0,060
-
Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):e25-32.
Score: 0,055
-
Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. Int J STD AIDS. 2009 Dec; 20(12):858-62.
Score: 0,045